320 related articles for article (PubMed ID: 27116020)
21. Possibility of extending biopharmaceutics classification system based biowaiver to BCS class IIa drug.
Khalid F; Hassan SMF; Noor R; Zaheer K; Hassan F
Pak J Pharm Sci; 2019 Sep; 32(5):2065-2073. PubMed ID: 31813872
[TBL] [Abstract][Full Text] [Related]
22. Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Metformin Hydrochloride.
Metry M; Shu Y; Abrahamsson B; Cristofoletti R; Dressman JB; Groot DW; Parr A; Langguth P; Shah VP; Tajiri T; Mehta MU; Polli JE
J Pharm Sci; 2021 Apr; 110(4):1513-1526. PubMed ID: 33450218
[TBL] [Abstract][Full Text] [Related]
23. Summary workshop report: bioequivalence, biopharmaceutics classification system, and beyond.
Polli JE; Abrahamsson BS; Yu LX; Amidon GL; Baldoni JM; Cook JA; Fackler P; Hartauer K; Johnston G; Krill SL; Lipper RA; Malick WA; Shah VP; Sun D; Winkle HN; Wu Y; Zhang H
AAPS J; 2008 Jun; 10(2):373-9. PubMed ID: 18679807
[TBL] [Abstract][Full Text] [Related]
24. Application of in vitro biopharmaceutical methods in development of immediate release oral dosage forms intended for paediatric patients.
Batchelor HK; Kendall R; Desset-Brethes S; Alex R; Ernest TB;
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):833-42. PubMed ID: 23665448
[TBL] [Abstract][Full Text] [Related]
25. Drug Permeability - Best Practices for Biopharmaceutics Classification System (BCS)-Based Biowaivers: A workshop Summary Report.
Mehta M; Polli JE; Seo P; Bhoopathy S; Berginc K; Kristan K; Cook J; Dressman JB; Mandula H; Munshi U; Shanker R; Volpe DA; Gordon J; Veerasingham S; Welink J; Almeida S; Gonzalez P; Painter D; Tsang YC; Vaidyanathan J; Velagapudi R
J Pharm Sci; 2023 Jul; 112(7):1749-1762. PubMed ID: 37142122
[TBL] [Abstract][Full Text] [Related]
26. BCS-based biowaivers: Extension to paediatrics.
Martir J; Flanagan T; Mann J; Fotaki N
Eur J Pharm Sci; 2020 Dec; 155():105549. PubMed ID: 32941998
[TBL] [Abstract][Full Text] [Related]
27. Very rapid dissolution is not needed to guarantee bioequivalence for biopharmaceutics classification system (BCS) I drugs.
Kortejärvi H; Shawahna R; Koski A; Malkki J; Ojala K; Yliperttula M
J Pharm Sci; 2010 Feb; 99(2):621-5. PubMed ID: 19844950
[TBL] [Abstract][Full Text] [Related]
28. Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Levetiracetam.
Petruševska M; Berglez S; Krisch I; Legen I; Megušar K; Peternel L; Abrahamsson B; Cristofoletti R; Groot DW; Kopp S; Langguth P; Mehta M; Polli JE; Shah VP; Dressman J
J Pharm Sci; 2015 Sep; 104(9):2676-87. PubMed ID: 25663270
[TBL] [Abstract][Full Text] [Related]
29. A Survey of the Regulatory Requirements for BCS-Based Biowaivers for Solid Oral Dosage Forms by Participating Regulators and Organisations of the International Generic Drug Regulators Programme.
Van Oudtshoorn JE; García-Arieta A; Santos GML; Crane C; Rodrigues C; Simon C; Kim JM; Park SA; Okada Y; Kuribayashi R; Pfäffli C; Nolting A; Lojero IOC; Martínez ZR; Hung WY; Braddy AC; Leal NA; Triana DG; Clarke M; Bachmann P
J Pharm Pharm Sci; 2018; 21(1):27-37. PubMed ID: 29382433
[TBL] [Abstract][Full Text] [Related]
30. Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?
Alqahtani S; Seoane-Vazquez E; Rodriguez-Monguio R; Eguale T
Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):709-15. PubMed ID: 26013294
[TBL] [Abstract][Full Text] [Related]
31. ICH Guideline for Biopharmaceutics Classification System-Based Biowaiver (M9): Toward Harmonization in Latin American Countries.
Miranda C; Aceituno A; Fernández M; Mendes G; Rodríguez Y; Llauró V; Cabrera-Pérez MÁ
Pharmaceutics; 2021 Mar; 13(3):. PubMed ID: 33801796
[TBL] [Abstract][Full Text] [Related]
32. Scientific considerations to move towards biowaiver for biopharmaceutical classification system class III drugs: How modeling and simulation can help.
Wu F; Cristofoletti R; Zhao L; Rostami-Hodjegan A
Biopharm Drug Dispos; 2021 Apr; 42(4):118-127. PubMed ID: 33759204
[TBL] [Abstract][Full Text] [Related]
33. Biowaiver monographs for immediate release solid oral dosage forms: piroxicam.
Shohin IE; Kulinich JI; Ramenskaya GV; Abrahamsson B; Kopp S; Langguth P; Polli JE; Shah VP; Groot DW; Barends DM; Dressman JB
J Pharm Sci; 2014 Feb; 103(2):367-77. PubMed ID: 24301077
[TBL] [Abstract][Full Text] [Related]
34. Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Proguanil Hydrochloride.
Plöger GF; Abrahamsson B; Cristofoletti R; Groot DW; Langguth P; Mehta MU; Parr A; Polli JE; Shah VP; Tajiri T; Dressman JB
J Pharm Sci; 2018 Jul; 107(7):1761-1772. PubMed ID: 29571740
[TBL] [Abstract][Full Text] [Related]
35. The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension.
Lennernäs H; Abrahamsson B
J Pharm Pharmacol; 2005 Mar; 57(3):273-85. PubMed ID: 15807982
[TBL] [Abstract][Full Text] [Related]
36. Regulatory Perspectives on Strength-Dependent Dissolution Profiles and Biowaiver Approaches for Immediate Release (IR) Oral Tablets in New Drug Applications.
Suarez-Sharp S; Delvadia PR; Dorantes A; Duan J; Externbrink A; Gao Z; Ghosh T; Miksinski SP; Seo P
AAPS J; 2016 May; 18(3):578-88. PubMed ID: 26928450
[TBL] [Abstract][Full Text] [Related]
37. Investigating the Discriminatory Power of BCS-Biowaiver in Vitro Methodology to Detect Bioavailability Differences between Immediate Release Products Containing a Class I Drug.
Colón-Useche S; González-Álvarez I; Mangas-Sanjuan V; González-Álvarez M; Pastoriza P; Molina-Martínez I; Bermejo M; García-Arieta A
Mol Pharm; 2015 Sep; 12(9):3167-74. PubMed ID: 26287948
[TBL] [Abstract][Full Text] [Related]
38. Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Carbamazepine.
García MA; Cristofoletti R; Abrahamsson B; Groot DW; Parr A; Polli JE; Mehta M; Shah VP; Tomakazu T; Dressman JB; Langguth P
J Pharm Sci; 2021 May; 110(5):1935-1947. PubMed ID: 33610571
[TBL] [Abstract][Full Text] [Related]
39. To what degree are review outcomes aligned for new active substances (NASs) between the European Medicines Agency and the US Food and Drug Administration? A comparison based on publicly available information for NASs initially approved in the time period 2014 to 2016.
Kühler TC; Bujar M; McAuslane N; Liberti L
BMJ Open; 2019 Nov; 9(11):e028677. PubMed ID: 31772082
[TBL] [Abstract][Full Text] [Related]
40. Donepezil Hydrochloride BCS Class Ambiguity: Relevant Aspects to be Considered in Drug Classification.
de Campos DP; Silva-Barcellos NM; Caldeira TG; Mussel WDN; Silveira V; de Souza J
J Pharm Sci; 2022 Nov; 111(11):3064-3074. PubMed ID: 35787368
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
